RecruitingPhase 3NCT05895786
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-06823859(drug)
- Enrollment
- 318 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Arizona Arthritis & Rheumatology Associates, P.C., Glendale, Arizona, United States
- Mayo Clinic Hospital, Phoenix, Arizona, United States
- Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona, United States
- 200 UCLA Medical Plaza, Los Angeles, California, United States
- UCLA Clinical & Translational Research Center (CTRC), Los Angeles, California, United States
- UCLA, Los Angeles, California, United States
- Center for Clinical Research - Chapman Pavilion, Orange, California, United States
- UCI Douglas Hospital, Orange, California, United States
- UCI Health Center for Innovative Health Therapies, Orange, California, United States
- University of California - Irvine, Orange, California, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Lal Bhagchandani, M.D, Margate, Florida, United States
- University of Miami, Miami, Florida, United States
- University of Miami Dermatology Clinical Trials Unit, Miami, Florida, United States
- Unviversity of Miami, Miami, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05895786 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH